Skip to content

Significance of the High-risk Hpv Viral Load

Significance of the High-risk Hpv Viral Load

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00682812
Enrollment
149
Registered
2008-05-22
Start date
2008-06-16
Completion date
2023-05-23
Last updated
2023-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV Infections

Brief summary

The aim of this study is to evaluate the significance of an elevated high-risk HPV (HR-HPV) viral load.

Detailed description

We will particularly evaluate if the HR-HPV viral load: * Is correlated to the transcription of the genes of the oncoproteins E6 and E7 * Is predictive of the integration of the virus in infected cells * Is predictive of the presence of HPV in patients' blood * Influences the local and systemic immunologic response

Interventions

OTHER2 cervical takings and 2 sampling of blood

* 2 cervical takings * 2 sampling of blood before and after the total hysterectomy

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The women consulting for the therapeutic care (by hysterectomy or conization) of a LIEHG or a cervical cancer (carcinoma epidermoid or adenocarcinoma) confirmed by the anatomopathologique analysis of a preoperative cervical biopsy. * The women having a normal cervix consulting for the surgical care by hysterectomy of a good-hearted pathology of the womb. The normality of the cervix will be confirmed by the anatomopathologique analysis of the detail of hysterectomy * The patients participating in this study will have to be of more than 18 years old. All the subjects will be profitable of a regime of Social Security.

Exclusion criteria

* The patients having a LIEBG * The patients incapable to receive the information enlightened on the progress and the objectives of the study * The patients not having signed enlightened assent

Design outcomes

Primary

MeasureTime frame
Estimate the meaning of a viral load raised in HPV oncogenic36 months

Secondary

MeasureTime frame
To estimate the correlation enters the vorale load of the HPV oncogenic and the severity of the cervical hurt36 months
Estimate the correlation between the viral load of the HPV oncogenic and the level of transcription of the genes coding for oncoproteines E6 and E736 months
Estimate the correlation between the viral load in HPV oncogenic and the integration of the viral genome in that of the infected cells36 months
Estimate the correlation between a viral load raised in HPV oncogenic and a presence of HPV in the circulating blood of the infected patients36 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026